pediatric
-
US FDA grants pediatric exclusivity to PLAVIX
US FDA has granted Bristol-Myers Squibb and sanofi -aventis an additional six-month period of exclusivity to market Plavix (clopidogrel bisulfate). Exclusivity for PLAVIX in the US is now scheduled to expire on May 17, 2012. PLAVIX is marketed by …
pediatric | 27 January 2011
-
Novartis Granted Pediatric Indication for Hypertension Treatment
The European Commission (EC) has granted Diovan (valsartan) a pediatric indication for the treatment of hypertension in children and adolescents 6-18 years of age. Following the Commission's decision, the pediatric indication needs to be implemented …
pediatric | 13 May 2010
